The Senotherapeutics Biomarker Consortium (SBC) has been launched to standardize the measurement of senescence, uniting academia, industry, and regulators in a precompetitive effort. This initiative, spearheaded by Marco Quarta, Nicola Neretti, Heinrich Jasper, and Marco Demaria under the Phaedon Institute, aims to address the growing disconnect between therapeutic ambitions and the methodologies used to define and measure senescent cells in clinical settings.

This collaboration is crucial as the field of senotherapeutics has reached a translational inflection point, where the rapid proliferation of therapeutic ideas outpaces the development of reliable measurement tools. Current biomarkers are insufficient, often failing to capture the functional nuances of senescence, which can vary dramatically across contexts. The SBC’s approach focuses on creating multimodal panels that integrate various biological signatures, enabling a more accurate reflection of cellular behavior and its implications for healthspan.

The SBC represents a pivotal moment for the field, emphasizing the need for shared standards in biomarker development. By fostering collaboration and aligning methodologies, the consortium aims to enhance the reproducibility and interpretability of clinical trials, ultimately paving the way for more effective interventions in aging and related diseases.

Source: longevity.technology